/publications/issue/2011/June2011/Old-Drugs-Are-New-Again-

Old Drugs Are New Again

Author: Kathryn L. Hahn, PharmD, CPE, DAAPM

Unique formulations, new indications, and the 'rediscovery' of already approved drugs are just a few of the innovations pharmacists can expect as drug makers revitalize their product portfolios.


The current environment for drug development is putting increasing pressure on the pharmaceutical industry to consider innovative ways to supplement the development of new molecular entities by repurposing or repositioning older drugs with known track records for efficacy and safety.

Challenges to New Drug Development

New drug development is a high-risk business with the potential for high reward but also with the possibility of significant loss. On average, it takes 10 to 15 years to bring either a new molecular entity or a biologic to market, at an estimated cost of approximately $800 million to $1.7 billion.1-4 Of the drugs that receive approval from the FDA, approximately 2 in 10 are able to recoup development costs.4

In order to bring 1 new drug to market, many thousands of compounds are screened and discarded before a promising few reach the first round of clinical trials.4

Of the compounds that do enter clinical testing, it is estimated that, overall, the new drug approval rate is only 19%.5 In 2009, just 19 new molecular entities were approved by the FDA’s Center for Drug Evaluation and Research—a number that has remained relatively constant since 2005, but represents a significant decline from the peak of 53 in 1996.6,7

A key concern in the approval process—and an important cause of drug failure—is the toxicity-to-benefit ratio and long-term safety profile of an investigational drug. The high-profile withdrawal of drugs such as cerivastatin (Baycol) and rofecoxib (Vioxx) from the market due to safety concerns has reinforced the need for phase 4 postmarketing or safety surveillance studies and has triggered increased scrutiny of safety data by regulatory authorities.1

In addition to the challenges of the time and cost required to bring new drugs to market, the pharmaceutical industry is faced with dwindling product pipelines and imminent patent expirations on many drugs, including several “blockbusters,” such as atorvastatin (Lipitor). It is estimated that 71 drugs will face first-time generic competition between 2010 and 2015.8 It is further projected that drugs with sales of more than $73 billion from the 10 largest pharmaceutical companies will be exposed to generic competition between 2009 and 2012.9

Benefits of Repurposing Older Drugs

Repurposing drugs is not new to the pharmaceutical industry. There are numerous effective therapeutic agents whose side effect profiles have been documented over long-term use in clinical settings that are potential candidates for repurposing. In fact, approximately two-thirds of new drug applications submitted to the FDA are for modifications of existing drugs or their indications.7

Classic life-cycle management of a branded drug often includes extending the value and life of the drug by innovative strategies such as reformulation, finding new indications, or rediscovering the inherent value of an old drug—all of which are intended to provide added benefit to patients.

Reformulation

Many drugs may benefit from new and innovative technologies that improve drug delivery systems, such as chewable tablets, oral liquids, or conversion of intravenous to noninjectable forms of delivery. For example, a different route of administration, such as conversion from oral to transdermal, may lower the dose required, permit a new indication, or reduce toxicity. Conversion to extendedrelease technology decreases dosing frequency, which may increase adherence and decrease side effects by altering intestinal absorption.10-12

New Indications

New applications or indications for drugs can be discovered systematically by means of sophisticated computer programs or serendipitously by noting unexpected, but beneficial, side effects of treatment. In some cases, targets of a known drug that are clinically relevant in one biologic pathway or disease may be relevant in other pathways or diseases as well. It is also possible to take advantage of drugs that interact with multiple targets by developing a new indication where a secondary target is more relevant.13 A partial list of repurposed drugs is shown in the Table.2,14,15

Rediscovery of Old Drugs

Older drugs that have been overshadowed by advances in new drug development technologies, such as rational structurebased drug design and high-throughput screening (drug discovery experimentation that uses automated systems), may be revitalized when newer drugs either do not live up to their therapeutic potential or elicit an increased risk-to-benefit ratio over time.16

For industry, repurposing or repositioning of already-approved drugs is a lower-risk strategy that can reduce the cost and accelerate the time needed to bring the drug to market. Pharmacologic and safety profiles have been established; smaller, more rapid clinical trials may be carried out; and the manufacturing process may require only minimal modification.13 Furthermore, for drugs that may be nearing expiry, the Hatch—Waxman Act offers additional protection by granting 3-year market exclusivity rights to the new version of the drug.7,17

Although there are many diseases and conditions that have benefited from repurposed drugs, the management of hypertension in the primary care setting and supportive care in the oncology setting represent therapeutic areas in which there are significant unmet patient needs that repurposed drugs have the potential to address.

Management of Hypertension and Chronic Heart Failure

The prevalence of hypertension in the United States has essentially remained unchanged since 1999, varying from 28% to 30% of the adult population. An additional 28% have prehypertension (systolic blood pressure [BP] of 120-139 mm Hg or diastolic BP of 80-89 mm Hg).

Despite the fact that high BP is a modifiable risk factor for cardiovascular disease (CVD), only 68% of adults with hypertension are treated with antihypertensives, and, of those, only 64% are treated successfully, indicating that appropriate management of hypertension is a significant ongoing medical need.18 Numerous drugs representing several classes of antihypertensive agents are currently available. These drugs must be used in combination therapy to control BP in the majority of patients.19

The antihypertensive drug classes include:

• Diuretics (thiazide, loop, potassium-sparing)

• Aldosterone receptor blockers

• Beta-blockers (with/without intrinsic sympathomimetic activity)

• Combined alpha- and beta-blockers

• Angiotensin-converting enzyme (ACE) inhibitors

• Angiotensin II antagonists

• Calcium channel blockers (nondihydropyridines, dihydropyridines)

• Alpha1-blockers

• Central alpha2 -agonists and other centrally acting drugs

• Direct vasodilators

Currently, the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommends thiazide diuretics as the preferred initial agent for treating uncomplicated hypertension. Results from ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), among others, have consistently shown that thiazide diuretics are unsurpassed in reducing the risk of CVD and renal complications.19,20 However, despite their efficacy, tolerability, and modest cost, they remain underutilized.19

Spironolactone (Aldactone), a potassium-sparing diuretic that acts as an aldosterone receptor antagonist, is an example of an old drug that has seen a recent resurgence of interest.21 With the introduction of ACE inhibitors—which decrease urinary excretion of potassium by blocking angiotensin II–mediated production of aldosterone—the use of spironolactone fell out of favor after a spike in patients with serious hyperkalemia was observed when ACE inhibitors and spironolactone were used concomitantly.22 However, spironolactone usage increased following publication of RALES (Randomized Aldactone Evaluation Study), which demonstrated a 30% lower risk of morbidity and mortality in patients with severe heart failure and systolic left ventricular dysfunction who had received low-dose spironolactone.23,24 LowTable partial list of repurpose drugs spironolactone has also been shown to be effective in the treatment of resistant hypertension.25

Nonselective beta-blockers are an example of the rediscovery of an older class of drugs. The first beta-blocker, propranolol (Inderal), was characterized by J.W. Black, MD, in the mid-1960s.26 Propranolol, which blocks both beta1- and beta2-adrenergic receptors, was overshadowed by the morespecific second-generation beta1 -adrenergic receptor blockers, such as metoprolol and atenolol.19,27 Carvedilol (Coreg), a third-generation beta-blocker, nonselectively blocks both beta1- and beta2-adrenergic receptors as well as the alpha1-adrenergic receptor, which increases peripheral vasodilation and renal sodium excretion.28 In the COMET (Carvedilol or Metoprolol European Trial) study, carvedilol significantly improved both survival and vascular outcomes, including stroke, myocardial infarction, and unstable angina compared with metoprolol.28

Minoxidil is an example of an old drug repurposed with a new indication and reformulation. Minoxidil (Loniten), a powerful peripheral vasodilator, is used in combination with other antihypertensives to treat severe or refractory high BP. In early studies, sodium retention and hirsutism were noted as significant side effects of minoxidil therapy.29 In the late 1980s, a topical preparation of minoxidil (Rogaine) was cleared by the FDA for male pattern baldness and androgenic alopecia; in the mid-1990s, 5% and 2% topical solutions of minoxidil were approved as OTC products.30,31 Reformulation to a 5% topical foam-based vehicle was assessed in a randomized, blinded clinical study that demonstrated significant improvement in hair counts and subjective assessment of hair loss condition and good tolerability compared with placebo. Thus, the foam formulation was found to be comparable to the solution with respect to performance and had the added benefit of enhanced cosmetic acceptability.30

Oncology Supportive Care

Patients with cancer may experience numerous treatment- and cancer-related complications that can have a substantial impact on quality of life. Two of the most-feared complications are chemotherapy-induced nausea and vomiting (CINV) and cancerrelated pain. Although pharmacologic interventions are available for both CINV and pain, response is still often inadequate.

Cannabinoids. Cannabis was first used medicinally by the Chinese approximately 5000 years ago. Around 1000 BC, cannabis was widely used in India for both its numerous therapeutic and psychoactive properties, for which it was often incorporated into religious rituals.32 In Western medicine, cannabis was commercialized during the late 19th and early 20th centuries and was removed from the US Pharmacopeia in 1941 only following passage of the Marijuana Tax Act.32

The discovery and characterization of the human endocannabinoid system and its receptors, CB1 and CB2 , in the early 1990s led to renewed interest in the medical benefits of cannabis derivatives.33 The CB1 receptor, which is expressed in both central and peripheral neuronal tissue, is particularly abundant in the brain; CB1 receptors are also present to a lesser extent in many organs.34,35 Thus, the synthetic cannabinoid agonists of CB1 receptors are examples of drugs whose target is expressed in several biologic pathways that can be used in more than 1 clinical context. Currently, cannabinoids are indicated in the United States for CINV (nabilone [Cesamet], dronabinol [Marinol]) and appetite stimulation (dronabinol) and in Canada for neuropathic pain secondary to multiple sclerosis (cannabidiol [Sativex]).36 The expected side effect profile of cannabinoids (eg, dizziness, euphoria, drowsiness) has also been well characterized.37

Cannabinoids in CINV. Overall, approximately 70% to 80% of all patients with cancer undergoing chemotherapy will experience CINV. 38 It has been further estimated that approximately 30% to 50% of patients with cancer will continue to experience CINV despite the use of appropriate standard antiemetic therapy.39

The use of cannabinoids such as nabilone for CINV is being rediscovered after being sidelined by newer, more effective agents such as the selective 5-HT 3 receptor antagonists (eg, ondansetron [Zofran] and palonosetron [Aloxi]) and the neurokinin-1 receptor antagonist aprepitant [Emend].40 The current National Comprehensive Cancer Network Clinical Practice Guidelines for Antiemesis include cannabinoids in their recommendations for breakthrough or refractory CINV in patients with inadequate response to standard therapies.38

Methadone for Chronic Pain. Patients with chronic cancer- or non–cancer-related pain are frequently treated with opioids to obtain relief. Synthetic methadone, first developed during World War II as an alternative opioid analgesic to morphine, has recently undergone a renaissance because of a better understanding of both its unique pharmacologic properties and the challenges associated with its management, as well as its relatively low cost.41-43 As clinicians are now taking a more enlightened approach to pain management, the usage of methadone has increased dramatically over the past decade.44

Once used almost exclusively in detoxification and maintenance programs for narcotic addiction, 45 methadone has recently been shown to be highly effective in opioid rotation schedules in the palliative care setting.46 The potent efficacy of methadone can be attributed to at least 3 different mechanisms of action: mu-opioid receptor agonism (levo-isomer), N-methyl-Daspartate antagonism (dextro-isomer), and monoamine reuptake inhibition.43,46 The variable pharmacokinetics and difficulty in establishing equianalgesic ratios when converting from another opioid present challenges to the use of methadone; however, these concerns have been addressed procedurally in guidelines and recommendations.45,47

Fentanyl for Cancer-Related Pain. Fentanyl, which was first synthesized in 1960, has more than 100 times the potency of morphine and was initially developed as an anesthetic.48 Fentanyl is a rapid-onset, short-acting, lipophilic opioid with selective activity for mu-receptors expressed primarily in the brain and spinal cord, but also in the gastrointestinal tract.49,50

Breakthrough pain, defined as a sudden and often intense exacerbation of pain that occurs against a background of otherwise controlled persistent pain, is a challenging aspect of cancer pain that occurs in approximately 65% of patients with persistent pain.51 Breakthrough pain is usually treated with oral short-acting opioids that are often ineffective because of delayed pain relief resulting from variable absorption, limited bioavailability due to first-pass metabolism, or patient symptoms such as dysphagia or nausea and vomiting.52

Reformulations of fentanyl such as those using transdermal (Duragesic) and transmucosal (Actiq [stick lozenge], Fentora [effervescent tablets]) modes of administration have improved drug delivery; fentanyl buccal soluble film [Onsolis] is a transmucosal delivery system that uses a small soluble adhesive polymer film applied to the buccal membrane to deliver fentanyl. This new technology delivers fentanyl faster and at higher plasma concentrations than does the lozenge with less patient effort51,52 and provides significant breakthrough pain relief at 30 minutes compared with placebo. In clinical trials, Onsolis was well-tolerated in the oral cavity, and there were no unexpected adverse events.51

Hydromorphone. Hydromorphone is an example of a short-acting potent opioid that requires frequent dosing (4- to 6-hour intervals) to achieve around-the-clock control of pain. Although extended-release formulations for opioids, which provide sustained drug delivery with either daily or twice-daily dosing, have been available for many years, a 24-hour extended-release hydromorphone product (Palladone) was withdrawn from the market in 2005 for potentially fatal reactions when taken with alcohol.53,54 In March 2010, a new extended-release formulation of hydromorphone (Exalgo) that uses an innovative and patented osmotic controlled-release oral delivery system (OROS Push-Pull) technology became available. With this technology, more uniform drug effects and better bioavailability have been reported, and the likelihood of alcohol-induced “dose-dumping” appears to be reduced.54,55

Counseling Patients About Prescriptions for Older Drugs

Patients who are prescribed an older drug may express concerns or have questions about the choice of drug—they may feel that the drug may not be as effective as a newer drug or they may worry that it may not be as safe or may have more side effects. If the drug has been repurposed, it will be important to reassure your patients that the new use of the drug or the new formulation has been approved by the FDA and, in fact, may be better tolerated or have an improved safety profile.

Furthermore, a larger number of patients will have been exposed to a repurposed drug, allowing for considerable clinical experience compared with a newly approved drug. In addition, the repurposed drug may be more convenient to take or may provide more consistent drug levels in the body than other products that are available for the patient’s disease.

In conclusion, the repurposing or reformulation of older drugs may help meet therapeutic needs more quickly than new drug development does, and it should provide benefits to patients by introducing new indications and formulations that improve drug delivery with potentially better safety profiles. PT


Dr. Hahn is an affiliate faculty member at Oregon State University College of Pharmacy and chair of the Oregon Pain Management Commission. She is also an American Pain Foundation State Action Leader and a pharmacy manager for Bi-Mart Corporation.


References

1.      Tamimi NA, Ellis P. Drug development: from concept to marketing! Nephron Clin Pract. 2009;113:c125-c131.

2.      Verma U, Sharma R, Gupta P, et al. New uses for old drugs: novel therapeutic options. Indian J Pharmacol. 2005;37(5):279-287.

3.      Drug development costs hit $1.7 billion. Outsourcing-Pharma.com Web site. www.drugresearcher.com/Research-management/Drug-development-costs-hit-1.7-billion. Accessed April 18, 2010.

4.      Pharmaceutical Research and Manufacturers of America. Pharmaceutical Industry Profile 2008. Washington, DC: PhRMA; March 2008.

5.      DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87(3):272-277.

6.      Hughes B. 2009 FDA drug approvals. Nat Rev Drug Discov. 2010;9(2):89-92.

7.      Research and development in the pharmaceutical industry. The Congress of the United States. Congressional Budget Office; October 2006.

8.      The generic onslaught. Forbes Web site. www.forbes.com/2006/06/23/drugs-patents-expiration-cz_mh_0623generics.html. Accessed June 4, 2010.

9.      Big pharma and alpha cliffs. Seeking Alpha Web site. http://seekingalpha.com/article/124895-big-pharma-and-patent-cliffs. Accessed May 13, 2010.

10.  Kefalides PT. New methods for drug delivery. Ann Intern Med. 1998;128(12 Pt 1):1053-1055.

11.  Reformulation trend capturing alpha. In-Pharma Technologist.com Web site.www.in-pharmatechnologist.com/Materials-Formulation/Reformulation-trend-capturing-pharma. Accessed April 19, 2010.

12.  www.minervahc.com/. Accessed April 19, 2010.

13.  Innovative strategies for drug repurposing. Drug Discovery & Development Web site. www.dddmag.com/innovative-strategies-for-drug.aspx. Accessed May 15, 2010.

14.  Aronson JK. Old drugs--new uses. Br J Clin Pharmacol. 2007;64(5):563-565.

15.  Teachning an old drug new tricks. Next Generation Pharmaceutical Web site.www.ngpharma.com/article/Teaching-an-old-drug-new-tricks/. Accessed May 13, 2010.

16.  Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 2009;22(2):119-125.

17.  US Food and Drug Administration Web site.www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079031.htm. Accessed May 13, 2010.

18.  Ostchega Y, Yoon SS, Hughes J, et al. Hypertension Awareness, Treatment, and Control — Continued Disparities in Adults: United States, 2005–2006. NCHS Data Brief (2008).www.cdc.gov/nchs/data/databriefs/db03.pdf.Accessed April 22, 2010.

19.  Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.

20.  Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med. 2009;169(9):832-842.

21.  Tang WH, Parameswaran AC, Maroo AP, Francis GS. Aldosterone receptor antagonists in the medical management of chronic heart failure. Mayo Clin Proc. 2005;80(12):1623-1630.

22.  Pitt B, Rajagopalan S. Aldosterone receptor antagonists for heart failure: current status, future indications. Cleve Clin J Med. 2006;73(3):257-260, 264-258.

23.  Pitt B, Zannad F, Remme WJ, et al; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure.  N Engl J Med. 1999;341(10):709-717.

24.  Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med.  2004;351(6):543-551.

25.  Goodfriend TL. Treating resistant hypertension with a neglected old drug. Hypertension. 2007;49(4):763-764.

26.  Black JW, Duncan WA, Shanks RG. Comparison of some properties of pronethalol and propranolol. Br J Pharmacol Chemother. 1965;25(3):577-591.

27.  de Boer RA, Voors AA, van Veldhuisen DJ. Nebivolol: third-generation beta-blockade. Expert Opin Pharmacother. 2007;8(10):1539-1550.

28.  Remme WJ, Torp-Pedersen C, Cleland JG, et al. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol. 2007;49(9):963-971.

29.  Joekes AM, Thompson FD, O’Regan PF. Clinical use of minoxidil (Loniten). J R Soc Med. 1981;74(4):278-282.

30.  Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767-774.

31.  FDA Clears Rogaine Hair Regrowth Treatment for OTC sale.  PSL Group Web site. www.pslgroup.com/dg960213c.htm.Accessed April 23, 2010.

32.  Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr. 2006;28(2):153-157.

33.  Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990;87(5):1932-1936.

34.  Sagar DR, Gaw AG, Okine BN, et al. Dynamic regulation of the endocannabinoid system: implications for analgesia. Mol Pain. 2009;5:59.

35.  The cannabinoid receptor (CB1 receptor). CNS Forum Web site. www.cnsforum.com/imagebank/item/Cannabin_CBI/default.aspx. Accessed May 13, 2010.

36.  Davis M, Maida V, Daeninck P, Pergolizzi J. The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer. 2007;15(1):63-71.

37.  Davis MP. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs. 2008;17(1):85-95.

38.  NCCN Clinical Practice Guidelines in Oncology: Antiemesis. V.1.2010

39.  Warr DG. Chemotherapy- and cancer-related nausea and vomiting. Curr Oncol. 2008;15(suppl 1):S4-S9.

40.  Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med.
2008;358:2482-2494.

41.  Trafton JA, Ramani A. Methadone: a new old drug with promises and pitfalls. Curr Pain Headache Rep. 2009;13(1):24-30.

42.  Shaiova L. The role of methadone in the treatment of moderate to severe cancer pain. Supp Cancer Ther. 2005;2(3):176-180.

43.  Lynch ME. A review of the use of methadone for the treatment of chronic non-cancer pain. Pain Res Manage. 2005;10:143-154.

44.  Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians’ (ASIPP) Guidelines. Pain Physician. 2008;11:S5-S62.

45.  Toombs JD, Kral LA. Methadone treatment for pain states. Am Fam Physician.2005;71:1353-1358.

46.  Parsons HA, de-la-Cruz, El Osta B, et al. Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer. 2010;116(2):520-528.

47.  Chou R. 2009 Clinical guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain: what are the key messages for clinical practice? Pol Arch Med Wewn. 2009;119(7-8):469-477.

48.  StanleyTH. The history and development of the fentanyl series. J Pain Symptom Manage. 1992;7(3 suppl):S3-S7.

49.  Mystakidou K, Tsilika E, Tsiatas M, Vlahos L. Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology. Int J Nanomed. 2007:2(1)49-54.

50.  Holzer P. Opioid receptors in the gastrointestinal tract. Regulatory Peptides. 2009;155:11-17.

51.  Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study[published online ahead of print November 25, 2009].  Ann Oncol. 2010;21(6):1308-1314.

52.  Vasisht N, Gever LN, Tagarro I, Finn AL. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin Drug Investig. 2009;29(10):647-654.

53.  Palladone pain drug pulled off the market. WebMD Web site. www.webmd.com/pain-management/news/20050714/palladone-pain-drug-pulled-off-market. Accessed May 13, 2010.

54.  Weinstein SM. A new extended release formulation (OROS®) of hydromorphone in the management of pain. Ther Clin Risk Manage. 2009;5:75-80.

55.  EXALGO™ (hydromorphone HCl) Extended-Release Tablets CII (NDA 21-217). [Package insert]. Anesthetic and Life Support Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee (23 September 2009).